文献速递乳腺外科

靶向腋窝清扫在经新辅助全身治疗的淋巴结阳性乳腺癌中的系统综述:标记物类型与放置时机的差异

Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: variation in type of marker and timing of placement.
PubMed 文献 · Br J Surg · 2024-01-01

该系统综述检索至2023年7月4日,纳入51项研究共4512例淋巴结阳性(cN+)乳腺癌患者,按标记物类型和放置时机分组。共识别6种标记物,一步法15项研究靶向淋巴结术中识别率从8/13至47/47不等,两步法41项研究影像识别率为49%至100%、术中识别率从17/24至100%。因研究异质性,无法确定最佳靶向淋巴结切除技术,两步法存在新辅助全身治疗后影像上未能识别标记靶向淋巴结的风险。

要点

  • 共识别6种标记物:导丝、125I粒子、99mTc、(电)磁/射频标记、黑墨和夹子。
  • 一步法(新辅助前放置)15项研究,靶向淋巴结术中识别率从8/13至47/47不等。
  • 两步法(新辅助后放置)41项研究,影像识别率为49%至100%,术中识别率从17/24至100%。

核心结论

  • 临床实践中使用多种靶向腋窝清扫操作方式;因研究异质性,无法确定在识别率和可行性方面的最佳靶向淋巴结切除技术。
  • 两步法存在新辅助全身治疗后影像上未能识别标记靶向淋巴结的风险。

研究设计与样本

  • 系统综述,检索PubMed和Embase至2023年7月4日,纳入随机对照试验、队列研究和病例对照研究,要求至少25例患者。
  • 排除仅行靶向淋巴结切除(不联合前哨淋巴结活检)或未尝试术中定位靶向淋巴结的研究。
  • 最终纳入51项研究,共4512例患者;按 definitive marker 和放置时机分组进行定性综合。
  • 使用美国国立卫生研究院(National Institutes of Health)质量评估工具评估研究质量。

主要发现

  • 共识别6种 definitive marker:导丝、125I标记粒子、99mTc、(电)磁/射频标记、黑墨和夹子。
  • 15项研究评估一步法,靶向淋巴结术中识别率从8/13至47/47不等。
  • 41项研究评估两步法,新辅助全身治疗后影像上标记靶向淋巴结识别率为49%至100%,术中靶向淋巴结识别率从17/24至100%不等。
  • 大多数研究(51项中的40项)质量评为 fair。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因研究异质性,无法确定在识别率和可行性方面的最佳靶向淋巴结切除技术。
  • 两步法存在新辅助全身治疗后影像上未能识别标记靶向淋巴结的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In node-positive (cN+) breast cancer treated with neoadjuvant systemic therapy, combining sentinel lymph node biopsy and targeted lymph node excision, that is targeted axillary dissection, increases accuracy. Targeted axillary dissection procedures differ in terms of the targeted lymph node excision technique. This systematic review aimed to provide an overview of targeted axillary dissection procedures regarding definitive marker type and timing of placement: before neoadjuvant systemic therapy (1-step procedure) or after neoadjuvant systemic therapy adjacent to a clip placed before the neoadjuvant therapy (2-step procedure). METHODS: PubMed and Embase were searched, to 4 July 2023, for RCTs, cohort studies, and case-control studies with at least 25 patients. Studies of targeted lymph node excision only (without sentinel lymph node biopsy), or where intraoperative localization of the targeted lymph node was not attempted, were excluded. For qualitative synthesis, studies were grouped by definitive marker and timing of placement. The targeted lymph node identification rate was reported. Study quality was assessed using a National Institutes of Health quality assessment tool. RESULTS: Of 277 unique records, 51 studies with a total of 4512 patients were included. Six definitive markers were identified: wire, 125I-labelled seed, 99mTc, (electro)magnetic/radiofrequency markers, black ink, and a clip. Fifteen studies evaluated one-step procedures, with the identification rate of the targeted lymph node at surgery varying from 8 of 13 to 47 of 47. Forty-one studies evaluated two-step procedures, with the identification rate of the clipped targeted lymph node on imaging after neoadjuvant systemic therapy varying from 49 to 100%, and the identification rate of the targeted lymph node at surgery from 17 of 24 to 100%. Most studies (40 of 51) were rated as being of fair quality. CONCLUSION: Various targeted axillary dissection procedures are used in clinical practice. Owing to study heterogeneity, the optimal targeted lymph node excision technique in terms of identification rate and feasibility could not be determined. Two-step procedures are at risk of not identifying the clipped targeted lymph node on imaging after neoadjuvant systemic therapy.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. de Wild SR, Koppert LB, van Nijnatten TJA, et al. Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: variation in type of marker and timing of placement. Br J Surg. 2024. PMID: 38531689. doi:10.1093/bjs/znae071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。